Defiance Daily Target 2X Long LLY ETF

Herbst Group LLC Purchases 1,925 Shares of Eli Lilly in Q4

Eli Lilly Requests UK to Increase Drug Prices in Exchange for Investment

Eli Lilly Announces Plan to Invest $3 Billion Over Decade to Expand Supply Chain in China

WHO Foundation and Eli Lilly Collaborate to Strengthen Obesity Care Systems

Eli Lilly's Clinical Trial Shows Significant Improvement in Psoriasis and Weight Loss with Zepbound and Taltz Combination

Eli Lilly and LiLai Pharmaceutical Co-develop Tolerability Therapy

Fusemachines

Erayak Power Solution

Smart Powerr

Sky Quarry

Cue BioPharma

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

ZeZentalis Pharma

XCF Global

Rackspace Tech

U Power

LABU

SBIO

LLYX

ELIL

IBBQ

Eli Lilly and Company has announced that Foundayo™ (orforglipron), a new oral GLP-1 medication for weight loss, is now available in the U.S. for adults with obesity or overweight. It can be accessed through LillyDirect® and telemedicine providers, with a starting price of $25 per month for insured individuals and $149 for those paying out of pocket. Foundayo is taken once daily without food or water restrictions and has shown significant weight loss results in clinical studies. However, it may cause side effects and is not recommended for use with other GLP-1 medications.

prnewswire

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Global Healthcare

Eli Lilly

ALPS Medical Breakthrough

iShares US Pharma

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Direxion Daily LLY Bull 2X Shares

VG Health

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

17:14 ETFoundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.

ARKG

ABBV

Eli Lilly, Abbott Laboratories, and AbbVie are highlighted as top pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in developing and selling various healthcare products, including diabetes medications and treatments for autoimmune diseases. Their stocks are influenced by clinical trials, regulatory changes, and market dynamics, making them both promising and volatile investments. Despite a Moderate Buy rating for Eli Lilly, analysts suggest other stocks may offer better investment opportunities.

Market Beat

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Abbvie

Abbott Laboratories

Best Pharmaceutical Stocks To Follow Now - April 12th

LLYZ

WGHTQ

WW International, Inc. has announced the addition of Eli Lilly's newly approved oral GLP-1 drug, Foundayo, to its Med+ program. This initiative aims to provide expanded treatment options for individuals with obesity or overweight. Eligible members can access this once-daily therapy, along with support from certified clinicians and the GLP-1 Success program. Pricing for self-pay patients starts at $149 per month, varying by dosage. Scott Honken, Chief Commercial Officer, emphasized the importance of this new offering in providing clinical support and guidance for members.

rttnews

Defiance Daily Target 2X Short LLY ETF

WW INTERNATIONAL INC

WW International Adds Lilly's GLP-1 Foundayo To Med+ Program

ELIS

Eli Lilly Weight-Loss Pill Becomes Available in U.S.

marketscreener

Direxion S&P Biotech Bear 3X

Direxion Daily LLY Bear 1X Shares

Eli Lilly Weight-Loss Pill Becomes Available in U.S.

Reuters

BUZZ-Weight Watchers jumps as it adds Lilly oral weight-loss pill to program

Amazon's pharmacy announced on Thursday the introduction of Eli Lilly's newly approved GLP-1 weight loss drug Foundayo, and will provide nationwide delivery services through Amazon's logistics network, supporting same-day delivery in nearly 3,000 cities, with plans to expand to about 4,500 areas by the end of the year. Amazon stated that remote areas can also enjoy next-day or two to three-day delivery services, which is faster than traditional mail-order pharmacies. Amazon's stock price rose more than 4% on Thursday

AASTOCKS

Roundhill AMZN WeeklyPay ETF

GraniteShares 2x Long AMZN Daily ETF

Amazon

Direxion Daily AMZN Bull 2X Shares

Amazon Pharmacy introduces Eli Lilly's weight loss oral medication, available for same-day delivery in over 3,000 cities

Sosei Group Corporation

Nxera Pharma Co - Achieves Second Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases

Eli Lilly and Co. is experiencing increased pressure in India due to the rise of lower-cost generic alternatives impacting sales of its diabetes and weight-loss drug, Mounjaro. Sales dropped from $14.6 million to $12.3 million in March as competitors entered the market, with semaglutide's market share rising to 33%. Despite Mounjaro's continued dominance, it has faced significant challenges. However, the recent FDA approval of Foundayo, a new oral GLP-1 treatment, has improved Lilly's competitive position in the market.

benzinga_article

Eli Lilly Faces Pressure In India As Cheaper GLP-1 Rivals Dent Mounjaro Sales

Eli Lilly anticipates its first-quarter earnings report will include an Intellectual Property and Research & Development (IPR&D) charge of $584 million

Wallstreetcn

Pharmaceutical giants Eli Lilly and Novo Nordisk are competing in the weight loss drug market. Eli Lilly's oral GLP-1 drug Foundayo has been approved in the United States for obese patients, offering higher patient compliance. Novo Nordisk's Wegovy oral tablet has also been approved but must be taken on an empty stomach, resulting in lower compliance. Analysis indicates that Foundayo performs excellently in terms of weight loss effects and cardiovascular risk indicators, which may impact Novo Nordisk

腾讯新闻 - 财经

Novo Nordisk AS

Defiance Daily Target 2X Long NVO ETF

The weight loss drug giants are at war

Johnson & Johnson's immunology drug Tremfya has regained the top position in TV drug ad spending, surpassing AbbVie with $50.3 million spent in March. AbbVie’s Skyrizi and Rinvoq followed with $42.1 million and $36.3 million, respectively. Other notable mentions include J&J's Caplyta and Eli Lilly's Zepbound, which also saw significant ad spending. The competition remains fierce as companies vie for the top spot in advertising expenditures for their drugs.

Fiercepharma

Johnson & Johnson

J&J's Tremfya retakes TV drug ad spending crown from AbbVie

AC Immune Secures Amended Tau Drug Collaboration with Lilly, Adds CHF 10 Million Upfront

Tip Ranks

AC Immune

AC Immune Secures Amended Tau Drug Collaboration with Lilly, Adds CHF 10 Million Upfront

ULTA

Ulta Beauty is experiencing increased demand for hair and skincare products due to the side effects of GLP-1 weight-loss drugs, which are popular among users. CEO Kecia Steelman highlighted that hair thinning and skin elasticity issues are prompting consumers to seek solutions. The trend is also linked to aging-skincare consumers. Meanwhile, competition in the GLP-1 market is intensifying, with companies like Eli Lilly and Novo Nordisk ramping up advertising efforts. Ulta's stock closed at $542.65, reflecting a slight increase.

Ulta Beauty

'Hair Loss With GLP-1s Is Real,' Ulta CEO Says As Weight Loss Drug Trend Boosts Hair, Skincare Sales

Novo Nordisk's Wegovy pill launch has led to a surge in demand, attracting new patients who previously avoided GLP-1 injections due to needle fear or high costs. Early users report varying experiences, with over 600,000 prescriptions written since January. Analysts note the pill's competitive pricing and brand recognition, but Novo's stock remains under pressure as it competes with Eli Lilly's upcoming GLP-1 product. The Wegovy pill is expected to contribute significantly to sales growth, with projections estimating an increase from $13.5 billion in 2026 to $18.9 billion by 2031.

CNBC

Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

FOCUS-Americans want weight-loss pills for cost and convenience

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Defiance Daily Target 2X Long LLY ETF(LLYX.US)

Defiance Daily Target 2X Long LLY ETF Stock Performance Chart

17:14 ETFoundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.

Best Pharmaceutical Stocks To Follow Now - April 12th

WW International Adds Lilly's GLP-1 Foundayo To Med+ Program

Eli Lilly Weight-Loss Pill Becomes Available in U.S.

BUZZ-Weight Watchers jumps as it adds Lilly oral weight-loss pill to program